Niels Væver Hartvig

Niels Væver Hartvig

Auto-generated profile, based on publicly available information

Niels Væver Hartvig

Novo Nordisk A/S Søborg Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2024 in Diabetes Care
Verified
Journal Article
Open access
PDF file
TDThomas P.A. Danne
Thomas P.A. Danne
MJMichael Joubert
Michael Joubert
NHNiels Væver Hartvig
Niels Væver Hartvig
AKAnne Kaas
Anne Kaas
NKNikoline Nygård Knudsen
Nikoline Nygård Knudsen
Julia MaderJulia Mader
Julia Mader
OBJECTIVE: To evaluate the association of insulin injection adherence, smart insulin pen engagement, and glycemic control using real-world data from 16 countries from adults self-administering basal insulin degludec and bolus insulin with a smart insulin pen (NovoPen 6 or NovoPen Echo Plus) alongside continuous glucose monitoring (CGM). RESEARCH DESIGN AND METHODS: Data were aggregated over 14-day periods. Treatment adherence was defined according to the number of missed basal and missed bolus insulin doses and smart pen engagement according to the number of days with data uploads. RESULTS: Data from 3,945 adults, including 25,157 14-day periods with ≥70% CGM coverage, were analyzed. On average, 0.2 basal and 6.0 bolus insulin doses were missed over 14 days. The estimated probability of missing at least one basal insulin dose over a 14-day period was 17.6% (95% CI 16.5, 18.7). Missing one basal or bolus insulin dose per 14 days was associated with a significant decrease in percentage of time with glucose levels in range (TIR) (3.9–10.0 mmol/L), of −2.8% (95% CI −3.7, −1.8) and −1.7% (−1.8, −1.6), respectively; therefore, missing two basal or four bolus doses would decrease TIR by >5%. Smart pen engagement was associated positively with glycemic outcomes. CONCLUSIONS: This combined analysis of real-world smart pen and CGM data showed that missing two basal or four bolus insulin doses over a 14-day period would be associated with a clinically relevant decrease in TIR. Smart insulin pens provide valuable insights into treatment injection behaviors.

5 November 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
JHJarl Hellman
Jarl Hellman
NHNiels Væver Hartvig
Niels Væver Hartvig
AKAnne Kaas
Anne Kaas
JMJonas Bech Møller
Jonas Bech Møller
MSMads Reinholdt Sørensen
Mads Reinholdt Sørensen
JJJohan Jendle
Johan Jendle
Aim: To evaluate whether both bolus insulin injection frequency and smart pen engagement were associated with changes in glycaemic control, using real‐world data from adults with type 1 diabetes (T1D). Materials and Methods: Adults using a smart pen (NovoPen 6) to administer bolus insulin (fast‐acting insulin aspart or insulin aspart) alongside continuous glucose monitoring were eligible for inclusion. Smart pen engagement was characterized by number of days with pen data uploads over the previous 14 days. Glycaemic control was evaluated by analysing glucose metrics. Results: Overall, data from 1194 individuals were analysed. The number of daily bolus injections was significantly associated with time in range (TIR; 3.9‐10.0 mmol/L [70‐180 mg/dL]; P < 0.0001). Individuals administering, on average, three daily bolus insulin injections had an estimated 11% chance of achieving >70% TIR. The probability of achieving >70% TIR increased with the mean number of daily bolus injections. However, the percentage of TIR was lower on days when individuals administered higher‐than‐average numbers of injections. The observed mean number of daily bolus injections administered across the study population was lower than the optimal number required to reach glycaemic targets (4.8 injections vs. 6‐8 injections). Smart pen engagement was significantly associated with improved TIR. Conclusions: Glycaemic control was associated with daily bolus insulin injection frequency and smart pen engagement. A treatment regimen combining an optimal bolus injection strategy, and effective smart pen engagement, may improve glycaemic control among adults with T1D.

28 August 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PAPeter Adolfsson
Peter Adolfsson
BGBruno Guerci
Bruno Guerci
NHNiels Væver Hartvig
Niels Væver Hartvig
AKAnne Kaas
Anne Kaas
NKNikoline Nygård Knudsen
Nikoline Nygård Knudsen
Julia MaderJulia Mader
Julia Mader
Aims: This observational study investigated changes in glycaemic control in people living with diabetes after initiating a connected insulin pen to administer their bolus insulin in routine clinical practice. Materials and methods: Data were collected from adults (≥18 years) with insulin‐treated diabetes who were using a continuous glucose monitoring (CGM) device and started administering bolus insulin using a connected insulin pen. Key glycaemic outcomes were time in range (TIR; 3.9–10.0 mmol/L), time above range (TAR; >10.0 mmol/L), and time below range (TBR; <3.9 and <3.0 mmol/L) in the overall population and for subgroups by country and by baseline TIR for individuals with 3 months of baseline CGM data. Results: Data were included from 86 133 individuals with a mean (standard deviation) age of 43.7 (15.7) years. There were small but statistically significant increases from baseline in TIR at month 3 (1.5%‐points), month 6 (1.4%‐points) and month 12 (1.1%‐points), and statistically significant decreases from baseline in TAR and TBR (<3.9 and <3.0 mmol/L) at month 3, month 6 and month 12. Increases in TIR were largest for those with the lowest baseline TIR (3‐month baseline average of <40% TIR). Increases in TIR were largest in Austria, with an increase in TIR of 4.7% at month 3. Conclusions: These real‐world data show that glycaemic outcomes improved after connected insulin pen initiation, especially in individuals with the highest unmet need (i.e., lowest baseline TIR). Combining a connected insulin pen with additional support, such as app‐based training or education, may further improve glycaemic control.

1 June 2020 in Diabetes
Verified
Journal Article
Closed access
SCSergiu-Bogdan Catrina
Sergiu-Bogdan Catrina
NHNiels V. Hartvig
Niels V. Hartvig
AKAnne Kaas
Anne Kaas
JMJonas Moller
Jonas Moller
AMAnn-Charlotte M. Mårdby
Ann-Charlotte M. Mårdby
JJJohan H. Jendle
Johan H. Jendle
Multiple daily insulin injections are an integral part of life for patients with type 1 diabetes (T1D). Moreover, patients’ schedules can change from day-to-day, further complicating T1D management. This study aimed to analyze daily injection patterns for patients with T1D. This post-hoc observational study included children and adults with T1D from Sweden using NovoPen® 6 with bolus insulin (primarily insulin aspart) and/or basal insulin (primarily insulin degludec). Injection data were uploaded via the Glooko® cloud system. Daily bolus and basal injections timing profiles were documented, weighting each dose relative to the total daily dose. Time difference between two consecutive basal insulin injections was used to evaluate basal timing variation. In total 159 adults and 47 children were included in the analysis, with a total of 38678 days of bolus injections and 17869 days of basal injections. The mean bolus daily injection profile displayed peaks at typical mealtimes but with substantial variation across patients and between adults and children (Figure 1). In those receiving insulin degludec timing of consecutive basal injections differed by more than 6 hr in ∼9% of the injections for adults and 7% for children. These real-world data give a unique insight into the bolus and basal adherence of pediatric and adult patients with T1D. Furthermore, the results illustrate the flexibility needed for basal injections to enable optimal management of T1D. Disclosure S. Catrina: None. N.V. Hartvig: Employee; Self; Novo Nordisk A/S. A. Kaas: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. J. Moller: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. A.M. Mårdby: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. J.H. Jendle: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Sanofi. Research Support; Self; Novo Nordisk A/S. Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Sanofi.